Skip to main content
Midas Edge

Allogene Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

ALLO$0.93-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Stockholders’ Equity
Shares · Amount
Balance - December 31, 2023168,642,238$169$2,075,252$(1,562,233)$(955)$512,233
Issuance of common stock upon exercise of stock options and vesting of RSUs1,551,7291793——794
Vesting of early exercised common stock——532——532
Stock-based compensation——11,924——11,924
Employee stock purchase plan259,000—856——856
Net loss———(65,000)—(65,000)
Net unrealized gain on available-for-sale investments————2828
Balance - March 31, 2024170,452,9671702,089,357(1,627,233)(927)461,367
Issuance of common stock upon exercise of stock options and vesting of RSU's415,483118——19
Stock-based compensation——13,559——13,559
Issuance of common stock from ATM offering250,000—1,021——1,021
Issuance of common stock from registered offering, net of commissions and offering costs of $4.7 million37,931,03538105,245——105,283
Net loss———(66,358)—(66,358)
Net unrealized gain on available-for-sale investments————147147
Balance - June 30, 2024209,049,4852092,209,200(1,693,591)(780)515,038
Issuance of common stock upon exercise of stock options and vesting of RSU's181,142—————
Stock-based compensation13,387——13,387
Employee stock purchase plan269,5101678——679
Net loss———(66,293)—(66,293)
Net unrealized gain on available-for-sale investments————937937
Balance - September 30, 2024209,500,137$210$2,223,265$(1,759,884)$157$463,748
Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance - December 31, 2022144,438,304$144$1,911,632$(1,234,968)$(9,926)$666,882
Issuance of common stock upon exercise of stock options and vesting of RSUs942,2761(1)———
Vesting of early exercised common stock——603——603
Stock-based compensation——18,770——18,770
Employee stock purchase plan359,75311,730——1,731
Net loss———(99,968)—(99,968)
Net unrealized gain on available-for-sale investments————3,9923,992
Balance - March 31, 2023145,740,3331461,932,734(1,334,936)(5,934)592,010
Issuance of common stock from ATM offering, net of commissions and offering costs of $1.6 million20,288,3302087,898——87,918
Issuance of common stock upon exercise of stock options and vesting of RSUs1,105,00111,605——1,606
Vesting of early exercised common stock——432——432
Stock-based compensation——16,594——16,594
Net loss———(79,232)—(79,232)
Net unrealized gain on available-for-sale investments————2,0832,083
Balance - June 30, 2023167,133,6641672,039,263(1,414,168)(3,851)621,411
Issuance of common stock from ATM offering, net of offering costs of $50.0 thousand606,23513,193——3,194
Issuance of common stock upon exercise of stock options and vesting of RSUs204,116—326——326
Vesting of early exercised common stock——432——432
Stock-based compensation——15,354——15,354
Employee stock purchase plan231,206—765——765
Net loss———(62,287)—(62,287)
Net unrealized gain on available-for-sale investments————1,4401,440
Balance - September 30, 2023168,175,221$168$2,059,333$(1,476,455)$(2,411)$580,635
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.